PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response

Theranostics are emerging as a pillar of cancer therapy that enable the use of single molecule constructs for diagnostic and therapeutic application. As poly adenosine diphosphate (ADP)-ribose polymerase 1 (PARP-1) is overexpressed in various cancer types, and is localized to the nucleus, PARP-1 can...

Descripción completa

Detalles Bibliográficos
Autores principales: Riad, Aladdin, Gitto, Sarah B., Lee, Hwan, Winters, Harrison D., Martorano, Paul M., Hsieh, Chia-Ju, Xu, Kuiying, Omran, Dalia K., Powell, Daniel J., Mach, Robert H., Makvandi, Mehran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766161/
https://www.ncbi.nlm.nih.gov/pubmed/33352773
http://dx.doi.org/10.3390/molecules25246029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766161/
https://www.ncbi.nlm.nih.gov/pubmed/33352773
http://dx.doi.org/10.3390/molecules25246029

Ejemplares similares